Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia
Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia
复制标题
DOI:
10.1097/01.iae.0000254896.78766.74
复制
发表时间:
2006-11-01
影响因子:
3.3
通讯作者:
Apte, Rajendra S.
中科院分区:
文献类型:
--
作者:
Tewari, Asheesh;Dhalla, Mandeep S.;Apte, Rajendra S.
ResultsThe mean age SD of the patients presenting with retinal detachment in this study was 63.2 10.3 years. They were 64 men and 36 women. Decreased vision was found in 82% of patients (66%, macular detachment; 10%, bubbly retinal detachment masking the macula; 6%, vitreous hemorrhage). Ten percent of patients were able to explain what a retinal detachment was, 20% had heard of it, and 70% had no knowledge of that condition. No significant difference was found between phakic or pseudophakic patients with regard to their knowledge of retinal detachment (P 0.4)(Fig. 1). Three of four patients who had a history of retinal detachment were able to give a definition for it.For 20% of patients, decreased vision was due to cataract, and for one patient (2%), it was due to inflammation, although he had had a previous retinal detachment. Only 8% of patients thought of retinal detachment (three patients had a history of retinal detachment, including one physician). Most patients (70%) had no hypothesis. The mean consultation time after decreased vision was 24 hours versus 75 hours after visual field amputation. Once they had made a decision to consult a physician, it took patients 33 hours on average to see an ophthalmologist. Consultation appointments were granted sooner when patients described vision loss than when they described visual field amputation. Only 30% of patients consulted their general practitioner before, including 18% by telephone. Direct access to the ophthalmologist was the preferred option.